生物医学科学杂志

  • 国际标准期刊号: 2254-609X
  • 期刊 h 指数: 15
  • 期刊引用分数: 5.60
  • 期刊影响因子: 4.85
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

A Note on the Diagnosis of Tumor Metastatic Disease

Natasha Nikon

Not only are brain metastases the most common intracranial neoplasm in adults, but they are also very common in lung cancer patients. The presence of prognostic factors like control of the primary tumor, functional performance status, age, and the number of brain metastases have been used to classify patients. Because some of these patients have a good prognosis, they may benefit from receiving more aggressive treatment. We will go over all of the treatment options for treating brain metastases, which are mostly caused by a lung cancer primary, in thisreview. We willspecifically concentrate on the selection of patientsfor combined modality treatment of brain metastases, such as stereotactic radiosurgery (SRS) and whole brain irradiation; utilizing radio sensitizers; and the neurocognitive impairments that resulted from either SRS or whole brain irradiation. Both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) benefit from prophylactic cranial irradiation (PCI) and its potential neurotoxicity are discussed, asisthe combination treatment of intrathoracic primary disease and solitary brain metastasis. WBRT with an integrated boost to the gross brain metastases, SRS to the surgical bed, fractionated stereotactic radiotherapy, and WBRT with epidermal growth factor receptor (EGFR) inhibitors are also investigated.

Keywords

Lung cancer; PCI; Neurotoxicity

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证